| AB-8939 for gata2 deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abatacept for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE + Melphalan for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| allogeneic hematopoietic stem cell transplantation + Pharmacological Study + CLOFARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ascorbic Acid for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ASTX727 for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromes | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATO + Ascorbic acid for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atorvastatin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine + Ascorbic Acid for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine + Venetoclax + Mobinitinib for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD3632 for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD3632 + Posaconazole for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CliniMACS + G-CSF + HPC,A Infusion + RITUXIMAB + BLINATUMOMAB + Cyclophosphamide + THIOTEPA + LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN + Mesna + FLUDARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CliniMacs TCR alpha-beta-Biotin system for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Danicopan for hemoglobinuria, paroxysmal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Darbepoetin alfa + canakinumab for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Donor mobilized PBSC infusion + G-CSF + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elritercept for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hematopoietic stem-cell transplantation for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Immediate HSCT Group for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Luspatercept for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blasts | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mobinitinib for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Momelotinib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nk-dli for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo for Oral Azacitidine for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pozelimab + cemdisiran for hemoglobinuria, paroxysmal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton Total Marrow Irradiation for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| RITUXIMAB + Cyclophosphamide + MP + Busulfan + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rivogenlecleucel + rimiducid for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Romiplostim for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rosuvastatin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxolitinib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxoprubart for hemoglobinuria, paroxysmal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax + Azacitidine for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Stem Cell Infusion + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + TREOSULFAN + FLUDARABINE + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blasts | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Venetoclax + AB-8939 for gata2 deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Venetoclax + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vitamin C (ascorbic acid) for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|